Skip to main content
. Author manuscript; available in PMC: 2021 Sep 16.
Published in final edited form as: Prostate. 2018 Aug 28;79(1):31–43. doi: 10.1002/pros.23708

FIGURE 1.

FIGURE 1

Treatment regimen and effect of TGF-β blockade on prostate tumor growth. Panel A, Dosing regimen of galunisertib administration (75 mg/kg body weight, twice/day via oral gavage for 2 weeks) as a monotherapy or in combination with the antiandrogen, enzalutamide. Vehicle control consisted of 1% Carboxymethylcellulose, 0.5% Sodium Lauryl Sulfate, 0.085% Povidone (for mini-trials 1 and 2) and of 25% DMSO and 75% PBS (Trial 3). Panel B, indicates the effect of the various treatments on prostate tumor weight. Galunisertib alone did not exert a significant effect on prostate tumor growth, but in response to the combination with enzalutamide there was a significant reduction in prostate tumor weight compared to vehicle control. (*), statistically significant difference at P < 0.05.

HHS Vulnerability Disclosure